PREECLAMPSIA FOUNDATION

Mirvie's RNA Blood Test Predicts Preeclampsia Risk Months Before Symptoms in Major Study

- Mirvie's blood test successfully identified 91% of preterm preeclampsia cases in women over 35 without pre-existing conditions, using RNA signatures detectable at 17.5-22 weeks gestation. - The study analyzed over 9,000 pregnancies and discovered molecular signatures that distinguish between severe and mild hypertensive disorders of pregnancy for the first time. - Preeclampsia rates have nearly doubled in the past decade, now affecting 1 in 12 pregnancies, highlighting the urgent need for better predictive tools. - The clinically validated test will be available under the Encompass brand, enabling proactive care plans including low-dose aspirin therapy months before symptoms appear.